What is AMBOSS?
AMBOSS operates a sophisticated knowledge platform designed to revolutionize how medical information is accessed and applied at the point of care. The platform serves both medical students, offering an interactive library and question bank for comprehensive study and exam preparation, and practicing physicians, providing evidence-based recommendations to support critical clinical decision-making. By integrating vast medical knowledge with practical application tools, AMBOSS aims to enhance medical education and improve patient outcomes.
How much funding has AMBOSS raised?
AMBOSS has raised a total of $298.6M across 3 funding rounds:
Series A
$5.6M
Series B
$33M
Other Financing Round
$260M
Series A (2017): $5.6M with participation from Cherry Ventures
Series B (2019): $33M led by Partech, Holtzbrinck Digital, Wellington Partners, Cherry Ventures, and Target Global
Other Financing Round (2025): $260M supported by Kirkbi, Lightrock, and M&G Investments
Key Investors in AMBOSS
Kirkbi
Kirkbi is a private holding and investment company that maintains majority ownership of the LEGO Group, focusing on sustainable long-term investments. Their portfolio includes significant stakes in Merlin Entertainments and renewable energy projects, alongside strategic investments in various companies and real estate.
Lightrock
Lightrock is a global sustainable investment platform managing over $5.5 billion, focusing on investing in purpose-driven businesses that address significant global challenges with a commitment to impact and returns. They invest in technology-driven growth-stage companies across sectors related to People, Planet, and Productivity.
M&G Investments
M&G Investments is a company operating in the Venture Capital & Private Equity industry, headquartered in Switzerland. It employs between 250-499 people and generates between $50M-$100M in revenue.
What's next for AMBOSS?
With the recent influx of major strategic investment, AMBOSS is poised for accelerated development and market penetration. The company's focus on evidence-based medicine and its comprehensive digital platform position it for significant expansion, potentially into new geographical markets or by enhancing its existing product offerings. This substantial backing suggests a strategic push towards solidifying its leadership in the medical technology space, likely involving further technological advancements and strategic partnerships to broaden its reach and impact on healthcare delivery.
See full AMBOSS company page
